In such a series, it will be important to add other biomarker indices that might be of value in determining the outcome, including but not limited to PADI2 [25], FGFR1[26], SOX2 [27], EZH2 and ALDH1 [28], all of which in other unrelated studies have been proposed to play a role in progression of early breast lesions to overt cancer. Here, EZH2 is linked to cancer.